{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:13:29Z","timestamp":1765808009205},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00277-022-04800-3","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T07:02:43Z","timestamp":1645858963000},"page":"1089-1096","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine"],"prefix":"10.1007","volume":"101","author":[{"given":"David J.","family":"Hermel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munveer S.","family":"Bhangoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Burian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Waalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Saven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"issue":"4","key":"4800_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood.V82.4.1277.1277","volume":"82","author":"BA Robbins","year":"1993","unstructured":"Robbins BA, Ellison DJ, Spinosa JC et al (1993) Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82(4):1277\u20131287","journal-title":"Blood"},{"issue":"24","key":"4800_CR2","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305\u20132315","journal-title":"N Engl J Med"},{"issue":"5","key":"4800_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","volume":"21","author":"GR Goodman","year":"2003","unstructured":"Goodman GR, Burian C, Koziol JA, Saven A (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21(5):891\u2013896","journal-title":"J Clin Oncol"},{"issue":"6","key":"4800_CR4","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","volume":"92","author":"A Saven","year":"1998","unstructured":"Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92(6):1918\u20131926","journal-title":"Blood"},{"issue":"14","key":"4800_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM198704023161401","volume":"316","author":"AS Spiers","year":"1987","unstructured":"Spiers AS, Moore D, Cassileth PA et al (1987) Remissions in hairy-cell leukemia with pentostatin (2\u2019-deoxycoformycin). N Engl J Med 316(14):825\u2013830","journal-title":"N Engl J Med"},{"issue":"5","key":"4800_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","volume":"129","author":"MR Grever","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA et al (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129(5):553\u2013560","journal-title":"Blood"},{"issue":"18","key":"4800_CR7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","volume":"373","author":"E Tiacci","year":"2015","unstructured":"Tiacci E, Park JH, De Carolis L et al (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373(18):1733\u20131747","journal-title":"N Engl J Med"},{"issue":"15","key":"4800_CR8","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","volume":"30","author":"RJ Kreitman","year":"2012","unstructured":"Kreitman RJ, Tallman MS, Robak T et al (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30(15):1822\u20131828","journal-title":"J Clin Oncol"},{"issue":"21","key":"4800_CR9","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","volume":"131","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Tallman MS, Robak T et al (2018) Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood 131(21):2331\u20132334","journal-title":"Blood"},{"issue":"3","key":"4800_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/bjh.12490","volume":"163","author":"R Chandran","year":"2013","unstructured":"Chandran R, Gardiner SK, Smith SD, Spurgeon SE (2013) Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol 163(3):407\u2013409","journal-title":"Br J Haematol"},{"issue":"6","key":"4800_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","volume":"145","author":"M Else","year":"2009","unstructured":"Else M, Dearden CE, Matutes E et al (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145(6):733\u2013740","journal-title":"Br J Haematol"},{"issue":"6","key":"4800_CR12","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.V88.6.1954.bloodjournal8861954","volume":"88","author":"MS Tallman","year":"1996","unstructured":"Tallman MS, Hakimian D, Rademaker AW et al (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 88(6):1954\u20131959","journal-title":"Blood"},{"issue":"2","key":"4800_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood-2013-06-508754","volume":"123","author":"JD Rosenberg","year":"2014","unstructured":"Rosenberg JD, Burian C, Waalen J, Saven A (2014) Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 123(2):177\u2013183","journal-title":"Blood"},{"issue":"5","key":"4800_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1600-0609.2006.00732.x","volume":"77","author":"O Paltiel","year":"2006","unstructured":"Paltiel O, Adler B, Barchana M, Dann EJ (2006) A population-based study of hairy cell leukemia in Israel. Eur J Haematol 77(5):372\u2013377","journal-title":"Eur J Haematol"},{"issue":"6","key":"4800_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/00130404-200511000-00004","volume":"11","author":"R Sawhney","year":"2005","unstructured":"Sawhney R, Sehl M, Naeim A (2005) Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 11(6):449\u2013460","journal-title":"Cancer J"},{"issue":"7","key":"4800_CR16","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.1998.16.7.2352","volume":"16","author":"H Gomez","year":"1998","unstructured":"Gomez H, Mas L, Casanova L et al (1998) Elderly patients with aggressive non-Hodgkin\u2019s lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16(7):2352\u20132358","journal-title":"J Clin Oncol"},{"key":"4800_CR17","doi-asserted-by":"crossref","unstructured":"Baraldi-Junkins CA, Beck AC, Rothstein G (2000) Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 14(1):45\u201361, viii.","DOI":"10.1016\/S0889-8588(05)70277-X"},{"issue":"23","key":"4800_CR18","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/jnci\/86.23.1766","volume":"86","author":"SB Yellen","year":"1994","unstructured":"Yellen SB, Cella DF, Leslie WT (1994) Age and clinical decision making in oncology patients. J Natl Cancer Inst 86(23):1766\u20131770","journal-title":"J Natl Cancer Inst"},{"key":"4800_CR19","doi-asserted-by":"crossref","unstructured":"Buske C, Hutchings M, Ladetto M, et al (2018) ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol. 29(3):544\u2013562.","DOI":"10.1093\/annonc\/mdx413"},{"issue":"24","key":"4800_CR20","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595\u20132603","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04800-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T09:06:23Z","timestamp":1649408783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04800-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4800"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04800-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,26]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was unable to be obtained due to the retrospective nature of the study, though all information is presented as a composite without any identifying information. Institutional Review Board approval was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}